Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Bal, C; Stoshikj, S; Renner, A; Milger, K; Skowasch, D; Schulz, C; Jandl, M; Schmidt, O; Ehmann, R; Zehetmayer, S; Taube, C; Hamelmann, E; Buhl, R; Korn, S; Idzko, M.
German Asthma Net: Characterisation of responders to anti-IL-5 and anti-IL-5(R) therapy.
Pulmonology. 2025; 31(1):2460868 Doi: 10.1080/25310429.2025.2460868
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Milger-Kneidinger Katrin

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

INTRODUCTION: Previous studies of anti-IL-5/IL-5(R) therapies in severe asthma found that response was mainly predicted by indicators of good baseline disease control. However, long-term response predictors remain unclear. METHODS: Responders to anti-IL-5/IL-5(R) therapy in the well-characterised, real-life, international German Asthma Net (GAN) registry were analysed using regression analyses. Response was defined by ≥50% reduction in exacerbations or corticosteroid dose, super-response by a complete stop of both, and remission additionally by controlled asthma (ACT score≥20). RESULTS: Seventy-seven percent of 347 patients (55% female, 56.6±12.3 years, follow-up 20.3±13 months) were responders and showed improved exacerbation rates, asthma control, and corticosteroid treatment reduction. Response was independently predicted by inhaled corticosteroid dose (odds ratio [OR] 1.5; p = 0.014), exacerbation rate (OR 1.2; p = 0.009), and treatment duration (OR 1.05, p = 0.023). Univariately, blood eosinophil counts notably predicted response (OR 12.4; p = 0.004). Super-response was inversely associated with corticosteroid dependence and depression. Remission was associated with the absence of systemic corticosteroids, better asthma control, and FEV1 in litre. CONCLUSIONS: These results underscore that long-term anti-IL-5/IL-5(R) therapy reduces exacerbation and corticosteroid burden, especially in patients with severe disease and high type 2 inflammatory burden. Contrastingly, low baseline corticosteroid use and markers of good asthma control predicted remission and super-responder status.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Female - administration & dosage

Asthma - drug therapy

Male - administration & dosage

Middle Aged - administration & dosage

Interleukin-5 - antagonists & inhibitors

Treatment Outcome - administration & dosage

Adrenal Cortex Hormones - therapeutic use, administration & dosage

Adult - administration & dosage

Aged - administration & dosage

Anti-Asthmatic Agents - therapeutic use, administration & dosage

Germany - epidemiology

Registries - administration & dosage

Administration, Inhalation - administration & dosage

Eosinophils - administration & dosage

Antibodies, Monoclonal, Humanized - therapeutic use, administration & dosage

Disease Progression - administration & dosage

Severity of Illness Index - administration & dosage

Find related publications in this database (Keywords)

Severe asthma

anti-IL-5/IL-5(R) therapy

responder

remission

biomarker

© Med Uni Graz • Imprint